About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Rheumatology Research Group (GRR) is focused on translational research in immunity-mediated inflammatory diseases (IMIDA), mainly in the area of rheumatology. The GRR is a multidisciplinary group made up of clinical specialists, biologists, bioinformaticians and laboratory technicians. The different research lines of the GRR emphasize the use of high-performance technologies for the study at the cellular and molecular level of the immununopathology of IMIDA, mainly chronic inflammatory arthritis and autoimmune systemic diseases.
At the clinical level, we have developed lines of research in very diverse areas of rheumatology, including chronic inflammatory arthritis (rheumatoid arthritis, spondyloarthropathies), systemic autoimmune diseases (lupus, myositis, Sjögren's syndrome), the study of musculoskeletal imaging, pediatric rheumatology (juvenile idiopathic arthritis, autoimmune systemic diseases, autoinflammatory syndromes), central sensitization syndromes and the study of bone metabolism. One of the main objectives of the GRR is the coordination of basic and clinical research to accelerate the transfer of knowledge to clinical practice and thus improve the quality of life of patients.
IP: Maria America Lopez Lasanta Collaborators: - Funding agency: AbbVie Ltd. Funding: 15000 Reference: FER/LOPEZ/2023 Duration: 15/10/2025 - 15/12/2026
IP: Cristina Solé Marce Collaborators: - Funding agency: Fundació Víctor Grífols i Lucas Funding: 6000 Reference: GRIFOLS/BECA/SOLE/2025 Duration: 12/11/2025 - 11/11/2026
IP: Josefina Cortes Hernandez Collaborators: Maria Royo Lopez Funding agency: Instituto de Salud Carlos III Funding: 276156.25 Reference: PI24/01743 Duration: 01/01/2025 - 31/12/2027
IP: María Alba Erra Duran Collaborators: Juan Jose De Agustin De Oro, Jordi Mollet Sánchez, Yolima Cossio Gil, Emmanuel Giménez García, Gloria Aparicio Español, Luis Coronel Tarancon Funding agency: Instituto de Salud Carlos III Funding: 57500 Reference: PI25/01718 Duration: 01/01/2026 - 31/12/2028
PhD student: Albert Gil Vila Director/s: Ernesto Trallero Araguas, Albert Selva O'Callaghan University: Year: 2024
PhD student: Estefania Moreno Ruzafa Director/s: Sara Marsal Barril University: Year: 2024
PhD student: Mireia Lopez Corbeto Director/s: Sara Marsal Barril, Antonio Julia Cano University: Year: 2023
PhD student: Milagros Tessy Calizaya Vargas Director/s: Tomás Fernández de Sevilla Ribosa, Tomás Fernández de Sevilla Ribosa University: Universitat Autònoma de Barcelona Year: 2022
PhD student: Andrea Pluma Sanjurjo Director/s: Sara Marsal Barril University: Year: 2022
PhD student: Miriam Almirall Bernabé Director/s: Sara Marsal Barril, Francesc Casellas Jordá University: Year: 2022
PhD student: Eloy Garcia Vives Director/s: Josefina Cortes Hernandez University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Maria Alba Erra Duran, Maria Alba Erra Duran, Maria Alba Erra Duran Director/s: Vicenç Fonollosa Pla University: Universidad Autònoma de Barcelona Year: 2017
PhD student: Ernesto Trallero Araguas Director/s: Albert Selva O'Callaghan, Moisés Labrador Horrillo University: Universidad Autònoma de Barcelona Year: 2011
PhD student: Antonio Julia Cano Director/s: Sara Marsal Barril University: Universidad Autònoma de Barcelona Year: 2010
The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.
The event, held as part of World Lupus Day, incorporated the perspective of people living with the disease to address the challenges associated with lupus.
The global biopharmaceutical company UCB has acquired the data and clinical knowledge business of IMIDomics, a spin-off of the Vall d’Hebron Institute of Research (VHIR).
